Treatment of uveitis with endoplasmic reticulum aminopeptidase 1 (ERAP1) inhibitors

Number of patents in Portfolio can not be more than 2000

United States of America

PATENT NO 12157891
APP PUB NO 20230250434A1
SERIAL NO

18046291

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present disclosure provides methods of treating subjects having uveitis, and methods of identifying subjects having an increased risk of developing uveitis.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • REGENERON PHARMACEUTICALS, INC.

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Baras, Aris Tarrytown, US 75 32
Coppola, Giovanni Tarrytown, US 29 32
Gelfman, Sahar Tarrytown, US 9 0
Ligocki, Ann Tarrytown, US 5 0
Mendez, Huergo Santiago Tarrytown, US 3 0
Moscati, Arden Tarrytown, US 5 0
Romano, Carmelo Tarrytown, US 31 132
Stahl, Eli A Tarrytown, US 5 0
Van, Zyl Tave Tarrytown, US 3 0
Weyne, Jonathan Tarrytown, US 5 0

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Jun 3, 2028
7.5 Year Payment $3600.00 $1800.00 $900.00 Jun 3, 2032
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jun 3, 2036
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00